Guangdong Province Institute of Gastroenterology

Xiaolin Wang(Research Assistant, Master's Supervisor)

Bachelor's degree: Zhengzhou University, Chemistry Deparment, Chemistry (2005)
Doctor of Philosophy: Wuhan University, College of Chemistry and Molecular Sciences, Organic Chemistry (2010)
Research Experience:
Sep. 2004-Jul. 2005, Zhengzhou University, Chemistry Deparment and Institute of Medical Science in Henan Province. The pharmacological study of some anti-cancer drugs.
Sep. 2005-Feb. 2011, Wuhan University, College of Chemistry and Molecular Sciences. Focus ono the interaction study of small molecule and nucleic acid. Paticipated in several projects, including synthesis and biological studies of lipophilic cyclic polyamines and porphyrin derivatives, surface modification of quantum dot and its application in biochemistry, cooperative research on DNA alkylation, design and synthesize azobenzene derivative and explore their biological application of photoregulating the conformation of telomere DNA.
Apr. 2011- Apr. 2013, Stanford University, School of Medicine, Postdoctoral fellow, Hepatocellular Carcinoma(HCC) diagnosis and treatment including development of probes for non-invasive cancer early detection and development of potential anti-cancer drugs.
Dec. 2013-Oct. 2014, the 6th hospital of Sun Yat-Sun Unviversity, research assistant
Nov. 2014 to present, the 6th hospital of Sun Yat-Sun Unviversity, Assistant researcher, Focus on investigation of biomarkers to diagnosis and treat colorectal cancer(CRC), and development of potential anti-CRC drugs.

1.X. Wang^#; J. Huang^#; Y. Zhou; S. Yan; X. Weng; X. Wu; M. Deng; X. Zhou*, Conformational switching of G-quadruplex DNA by photoregulation. Angew Chem Int Ed Engl 2010; 49 (31), 5305-5309.(Co-first author)
2.C. Jiang^#; J. Long^#; B. Liu^#; M. Xu; W. Wang; X. Xie; X. Wang*; M. Kuang*, miR-500a-3p promotes cancer stem cells properties via STAT3 pathway in human hepatocellular carcinoma. J Exp Clin Cancer Res 2017; 36 (1), 99.(Co-responding author)
3.Z. Li^#; X. Wang^#; H. Pan; H. Yang; X. Li; K. Zhang; H. Wang; Z. Zheng; H. Liu*; J. Wang*, Resistin promotes CCL4 expression through toll-like receptor-4 and activation of the p38-MAPK and NF-kappaB signaling pathways: implications for intervertebral disc degeneration. Osteoarthritis Cartilage 2017; 25(2):341-350. (Co-first author)
4.X. Xing^#; X. Wang^#; L. Xu; Y. Tai; L. Dai; X. Zheng; W. Mao; X. Xu; X. Zhou*, Light-driven conformational regulation of human telomeric G-quadruplex DNA in physiological conditions. Org Biomol Chem 2011; 9 (19), 6639-6645. (Co-first author)
5.H. C. Yu; Y. X. Luo*; X. L. Wang; L. L. Bai; P. Z. Huang; L. Wang; M. J. Huang; Y. H. Deng; J. P. Wang*, Time to lowest postoperative carcinoembryonic antigen level is predictive on survival outcome in rectal cancer. Sci Rep 2016; 6, 34131.
6.H. C. Yu; Y. X. Luo; H. Peng; X. L. Wang; Z. H. Yang; M. J. Huang; L. Kang; L. Wang; J. P*. Wang, Association of perioperative blood pressure with long-term survival in rectal cancer patients. Chin J Cancer 2016; 35, 38.
7.H. Yu; Y. Luo*; X. Wang; L. Kang; M. Huang; Y. Deng; L. Wang; J. Wang*, The effect of patterns of recurrence after radical resection of rectal cancer on long-term survival after recurrence. Natl Med J China 2016; 96 (8), 625-628.
8.L. Ma; X. Wang; T. Jia; W. Wei; M. S. Chua*; S. So, Tankyrase inhibitors attenuate WNT/beta-catenin signaling and inhibit growth of hepatocellular carcinoma cells. Oncotarget 2015; 6 (28), 25390-25401.
9.W. Wei; S. Wu; X. Wang; C. K. Sun; X. Yang; X. Yan; M. S. Chua*; S. So, Novel celastrol derivatives inhibit the growth of hepatocellular carcinoma patient-derived xenografts. Oncotarget 2014; 5 (14), 5819-5831.

10.S. Wu; Q. Cao; X. Wang; K. Cheng; Z. Cheng*, Design, synthesis and biological evaluation of mitochondria targeting theranostic agents. Chem Commun (Camb) 2014; 50 (64), 8919-8922.

11.X. Yang; H. Liu; C. K. Sun; A. Natarajan; X. Hu; X. Wang; M. Allegretta; R. D. Guttmann; S. S. Gambhir; M. S. Chua*; Z. Cheng*; S. K. So, Imaging of hepatocellular carcinoma patient-derived xenografts using (8)(9)Zr-labeled anti-glypican-3 monoclonal antibody. Biomaterials 2014; 35 (25), 6964-6971.

Current researches mainly focus on investigation of biomarkers to diagnosis and treat colorectal cancer(CRC), and development of potential anti-CRC drugs